Co-Diagnostics, Inc. (C97.F)

1.0400 -0.0200 (-1.89%) As of 03:52PM CEST. Market open.

Co-Diagnostics, Inc.

2401 South Foothill Drive
Suite D
Salt Lake City, UT 84109
United States
(801) 438-1036
https://www.codiagnostics.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 155

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dwight H. Egan	Chairman & CEO	390.24k	N/A	1953
Mr. Brian L. Brown CPA	CFO & Company Secretary	318.13k	N/A	1976
Mr. Richard David Abbott	President	N/A	N/A	1972
Dr. Brent C. Satterfield Ph.D.	Co-Founder & Member of Scientific Advisory Board	222.93k	N/A	1977
Mr. David Nielsen	Chief Operating Officer	N/A	N/A	N/A
Mr. Dan Bohrer CPA	Vice President of Finance & Accounting	N/A	N/A	N/A
Mr. Christopher Thurston	Chief Technology Officer	N/A	N/A	N/A
Dr. Mark Poritz Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Andrew Benson	Head of Investor Relations	N/A	N/A	N/A
Dr. Mayuranki Almaula	Senior Vice President of Overseas Operations & Strategic Alliances	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Corporate governance

Co-Diagnostics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.